Article
Pharmacology & Pharmacy
Hong-Hong Zhang, Xiao-Jing Du, Mei-Ling Deng, Lie Zheng, Dun-Chen Yao, Zhi-Qiang Wang, Qun-Ying Yang, Shao-Xiong Wu
Summary: This study retrospectively evaluated the efficacy and safety of apatinib in recurrent/progressive GBM patients. The results showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Mohamed E. El-Abtah, Michael R. Wenke, Pratik Talati, Melanie Fu, Daniel Kim, Akila Weerasekera, Julian He, Anna Vaynrub, Mark Vangel, Otto Rapalino, Ovidiu Andronesi, Isabel Arrillaga-Romany, Deborah A. Forst, Yi-Fen Yen, Bruce Rosen, Tracy T. Batchelor, R. Gilberto Gonzalez, Jorg Dietrich, Elizabeth R. Gerstner, Eva-Maria Ratai
Summary: This study aimed to use MR spectroscopic imaging to measure the ratio of myo-inositol to creatine in patients with recurrent glioblastoma treated with bevacizumab and investigate its predictive value for survivorship. The results showed that lower levels of myo-inositol to creatine ratio in intratumoral, contralateral, and peritumoral volumes were associated with poor survivorship and treatment failure.
Article
Clinical Neurology
David M. Peereboom, Xiaobu Ye, Tom Mikkelsen, Glenn J. Lesser, Frank S. Lieberman, H. Ian Robins, Manmeet S. Ahluwalia, Andrew E. Sloan, Stuart A. Grossman
Summary: RO4929097 showed no activity in recurrent GBM patients and demonstrated minimal inhibition of neurosphere formation in fresh tissue samples.
Editorial Material
Biochemistry & Molecular Biology
Adela Wu, Michael Lim
Summary: Combining oncolytic virus with immune checkpoint inhibition shows treatment responses and longer survival for immunologically 'cold' recurrent glioblastomas, but creative treatment strategies are still needed for highly anti-inflammatory tumors.
Editorial Material
Critical Care Medicine
Kai L. Homer, Jake Mandziuk, Alim Hirji, James Barrie, Steven R. Meyer, Eric Y. L. Wong, Lakshmi Puttagunta, Kieran M. Halloran
Summary: The case involves a 34-year-old Korean male with a history of various health issues including heart disease, eye condition, and a previous intracranial malignancy.
Article
Oncology
Chester Kao, Daniel J. George, Tian Zhang
Summary: The case demonstrates the potential of combination cabozantinib plus nivolumab therapy in salvaging disease control in refractory metastatic renal cell carcinoma, and highlights the potential efficacy of vascular endothelial growth factor inhibitors and immune checkpoint inhibitors combination therapy.
Article
Biochemistry & Molecular Biology
Yu Jin Kim, Jang Mi Han, Hye Jin Jung
Summary: The study demonstrated the potent inhibitory effects of berbamine on VEGF and BDNF-induced angiogenesis, without affecting endothelial cell viability. Berbamine suppressed angiogenesis by regulating specific signaling pathways and key regulators in GBM cells, suggesting its potential as a new antiangiogenic agent for the treatment of malignant brain tumors.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Danieli Rosane Dallemole, Thatiana Terroso, Aline de Cristo Soares Alves, Juliete Nathali Scholl, Giovana Ravizzoni Onzi, Rodrigo Ce, Karina Paese, Ana Maria Oliveira Battastini, Silvia Staniscuaski Guterres, Fabricio Figueiro, Adriana Raffin Pohlmann
Summary: The study evaluated a novel nanoformulation for the treatment of glioblastoma, demonstrating its cytotoxicity and antiangiogenic activity both in vitro and in vivo. The results suggest the therapeutic potential of the nanoformulation against GB, supporting further preclinical studies.
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Biochemistry & Molecular Biology
Marton Tompa, Zoltan Kraboth, Bence Galik, Bela Kajtar, Attila Gyenesei, Bernadette Kalman
Summary: This study reveals the immune evasion mechanism of glioblastoma through the suppression of the IL-7 receptor-mediated pathway, highlighting it as a potential new treatment target.
Article
Oncology
Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli
Summary: The study analyzed the outcomes of patients with metastatic renal cell carcinoma with sarcomatoid features treated with cabozantinib, showing its efficacy in pretreated patients. Female sex, bone metastases, and International Metastatic Renal Cell Carcinoma Database Consortium criteria were significant predictors of worse overall survival.
Article
Oncology
A. Bosio, G. Cerretti, M. Padovan, M. Caccese, L. Denaro, F. Chioffi, A. Della Puppa, V. Aldegheri, V. Guarneri, V. Zagonel, G. Lombardi
Summary: The aim of this study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) in patients with recurrent glioblastoma (GBM). The results showed that rechallenge with metronomic TMZ is a well-tolerated option for the treatment of recurrent GBM.
Review
Cell Biology
Xin Wang, Jie Lu, Gaochao Guo, Jinming Yu
Summary: For recurrent glioblastoma (rGB) patients, neoadjuvant anti-PD-1 therapy followed by surgery and adjuvant anti-PD-1 therapy can significantly improve overall survival. Additionally, tumor-specific peptide vaccination or CAR-T cell therapy has shown promise for treating rGB patients. Effective predictive biomarkers for clinical efficacy are needed, along with efforts to enhance T cell function through engineering techniques.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Megan Mantica, Jan Drappatz, Frank Lieberman, Constantinos G. G. Hadjipanayis, L. Dade Lunsford, Ajay Niranjan
Summary: The purpose of this study was to evaluate the overall survival (OS) in patients with recurrent glioblastoma (GBM) treated with Border Zone SRS plus bevacizumab. The results showed that there was no significant difference in survival between the BZ-SRS group and the institutional historical controls. However, secondary analysis revealed a trend towards improved 6-month progression-free survival (PFS-6).
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)